A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients with COVID-19
COVID-19 Inpatient | COVID-19 Outpatient
What is the purpose of this trial?
The purpose of this research study is to see if a medicine called CINVANTI can be used safely and effectively to treat adults hospitalized because of COVID-19. Aprepitant may help in the treatment of COVID-19 because aprepitant may reduce the inflammation caused by the virus and may also reduce the ability of the virus to divide and increase in numbers. Aprepitant may also reduce the cough associated with COVID-19. All participants will receive daily treatment of study drug for up to 14 days and will be followed weekly for 8 weeks.
- Ages18 years and older
- Trial withHeron Therapeutics, Inc.
- Start Date09/09/2020
- End Date02/27/2021
- Last Updated02/05/2021
- Study HIC#2000028569